Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Textual)

v3.7.0.1
Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 10 Months Ended 12 Months Ended
Jul. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired     $ 4,400,000
Warrant [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount     2,243,664
Fortress Biotech, Inc [Member]      
Annual Fee On Diluted Outstanding Equity, Percentage     2.50%
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired   $ 190,000 $ 4,400,000
Fortress Biotech, Inc [Member] | Common Stock [Member]      
Stock Issued During Period, Shares, Issued for Services   250,000  
Series A Preferred Stock [Member]      
Stock Issued During Period, Shares, Issued for Services   0 0
Series A Preferred Stock [Member] | Preferred Shares [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount     250,000
Series A Preferred Stock [Member] | Fortress Biotech, Inc [Member]      
Stock Issued During Period, Shares, Issued for Services 250,000    
Preferred Stock, Dividend Rate, Percentage 2.50%